Home » European Commission Approves New Formulation of Takeda’s Entyvio
European Commission Approves New Formulation of Takeda’s Entyvio
The European Comission has approved a subcutaneous formulation of Takeda Pharamceuticals’ Entyvio (vedolizumab) for treatment of ulcerative colitis and Crohn's disease.
The approval was based on the results of a phase 3 trial of the formulation as a maintenance therapy in adult patients. The participants achieved clinical response at week six following two doses of the intravenous formulation.
Takeda said the new formulation will be available in both a pre-filled syringe and a pre-filled pen.
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May